ERBB2 and sarcoma: In another phase 1/2 clinical study on T cells expressing human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor in patients with HER2-positive sarcomas, 4 of 17 showed SD (Table 3) [91].